Claire Henchcliffe

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2825479/publications.pdf

Version: 2024-02-01

44 papers	2,837 citations	331259 21 h-index	329751 37 g-index
44 all docs	44 docs citations	44 times ranked	4720 citing authors

#	Article	IF	Citations
1	Can google glassâ„¢ technology improve freezing of gait in parkinsonism? A pilot study. Disability and Rehabilitation: Assistive Technology, 2023, 18, 327-332.	1.3	7
2	Preclinical Efficacy and Safety of a Human Embryonic Stem Cell-Derived Midbrain Dopamine Progenitor Product, MSK-DA01. Cell Stem Cell, 2021, 28, 217-229.e7.	5.2	116
3	Tablet-based patient educational interventions in care and management of complex movement disorders. Disability and Rehabilitation: Assistive Technology, 2021, , 1-8.	1.3	0
4	Population-based input function for TSPO quantification and kinetic modeling with [11C]-DPA-713. EJNMMI Physics, 2021, 8, 39.	1.3	6
5	Comprehensive subtyping of Parkinsonâ€™s disease patients with similarity fusion: a case study with BioFIND data. Npj Parkinson's Disease, 2021, 7, 83.	2.5	14
6	Comparison of the Parkinsonâ€™s KinetiGraph to off/on levodopa response testing: Single center experience. Clinical Neurology and Neurosurgery, 2021, 209, 106890.	0.6	3
7	The future of stem cell therapies for Parkinson disease. Nature Reviews Neuroscience, 2020, 21, 103-115.	4.9	178
8	T165. ANTI-GLUTAMATERGIC PROPERTY OF N-ACETYLCYSTEINE DOCUMENTED IN VIVO WITH 1H MRS. Schizophrenia Bulletin, 2020, 46, S294-S294.	2.3	0
9	Molecular Imaging of Striatal Dopaminergic Neuronal Loss and the Neurovascular Unit in Parkinson Disease. Frontiers in Neuroscience, 2020, 14, 528809.	1.4	13
10	A machine learning and network framework to discover new indications for small molecules. PLoS Computational Biology, 2020, 16, e1008098.	1.5	8
11	Toward a Personalized Approach to Parkinson's Cell Therapy. Movement Disorders, 2020, 35, 2119-2120.	2.2	4
12	Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinsonâ€™s Disease. New England Journal of Medicine, 2020, 382, 1926-1932.	13.9	298
13	Restoring Function to Dopaminergic Neurons: Progress in the Development of Cell-Based Therapies for Parkinsonâ€™s Disease. CNS Drugs, 2020, 34, 559-577.	2.7	6
14	Neurophysiological Biomarkers of Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2020, 10, 471-480.	1.5	27
15	Comorbid neuropsychiatric and autonomic features in REM sleep behavior disorder. Clinical Parkinsonism & Related Disorders, 2020, 3, 100044.	0.5	3
16	Feasibility of Population-Based Input Function for Kinetic Analysis of [¹¹C]-DPA-713. , 2020, , .		1
17	Motor phenotype classification in moderate to advanced PD in BioFIND study. Parkinsonism and Related Disorders, 2019, 65, 178-183.	1.1	20
18	Data-Driven Subtyping of Parkinsonâ€™s Disease Using Longitudinal Clinical Records: A Cohort Study. Scientific Reports, 2019, 9, 797.	1.6	76

#	Article	IF	Citations
19	Sex and Gender Driven Modifiers of Alzheimerâ€™s: The Role for Estrogenic Control Across Age, Race, Medical, and Lifestyle Risks. Frontiers in Aging Neuroscience, 2019, 11, 315.	1.7	93
20	0652 Interim Analysis from the REM Sleep Behavior Disorder Associations with Parkinsonâ€™s Disease Study (RAPiDS). Sleep, 2019, 42, A260-A260.	0.6	0
21	18Fâ€FPEB PET/CT Shows mGluR5 Upregulation in Parkinson's Disease. Journal of Neuroimaging, 2019, 29, 97-103.	1.0	24
22	Repairing the Brain: Cell Replacement Using Stem Cell-Based Technologies. Journal of Parkinson's Disease, 2018, 8, S131-S137.	1.5	16
23	Noninvasive PK11195â€PET Image Analysis Techniques Can Detect Abnormal Cerebral Microglial Activation in Parkinson's Disease. Journal of Neuroimaging, 2018, 28, 496-505.	1.0	29
24	Rapid eye movement sleep behavior disorder and the link to alpha-synucleinopathies. Clinical Neurophysiology, 2018, 129, 1551-1564.	0.7	62
25	Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. Movement Disorders, 2018, 33, 282-288.	2.2	122
26	The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. Movement Disorders, 2016, 31, 924-932.	2.2	48
27	Future needs for informed consent in stem cell clinical trials in neurodegenerative diseases. Neural Regeneration Research, 2016, 11, 83.	1.6	4
28	Usefulness of Proton and Phosphorus MR Spectroscopic Imaging for Early Diagnosis of Parkinson's Disease. Journal of Neuroimaging, 2015, 25, 105-110.	1.0	43
29	First-in-human cell transplant trials in Parkinson's disease: The need for an improved informed consent process. Parkinsonism and Related Disorders, 2015, 21, 829-832.	1.1	16
30	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. JAMA Neurology, 2014, 71, 543.	4.5	312
31	Sex differences in cerebral energy metabolism in Parkinson's disease: A phosphorus magnetic resonance spectroscopic imaging study. Parkinsonism and Related Disorders, 2014, 20, 545-548.	1.1	20
32	Biomarkers in ParkinsonÊ¼s disease. Current Opinion in Neurology, 2012, 25, 460-465.	1.8	52
33	Potential Therapies for Mitochondrial Dysfunction. , 2012, , 215-230.		0
34	Disease Modification in ParkinsonÊ¼s Disease. Drugs and Aging, 2011, 28, 605-615.	1.3	31
35	Biomarkers of Parkinson's disease and Dementia with Lewy bodies. Progress in Neurobiology, 2011, 95, 601-613.	2.8	32
36	Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography. Clinical Ophthalmology, 2010, 4, 1427.	0.9	97

#	Article	IF	Citations
37	Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatric Disease and Treatment, 2009, 5, 597.	1.0	133
38	Metabolomic Profiling in LRRK2-Related Parkinson's Disease. PLoS ONE, 2009, 4, e7551.	1.1	142
39	Multinuclear Magnetic Resonance Spectroscopy for in Vivo Assessment of Mitochondrial Dysfunction in Parkinson's Disease. Annals of the New York Academy of Sciences, 2008, 1147, 206-220.	1.8	67
40	Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nature Clinical Practice Neurology, 2008, 4, 600-609.	2.7	643
41	Late-life depression: a neuropsychiatric approach. Expert Review of Neurotherapeutics, 2006, 6, 65-72.	1.4	23
42	Recent advances in Parkinsonâ€™s disease therapy: use of monoamine oxidase inhibitors. Expert Review of Neurotherapeutics, 2005, 5, 811-821.	1.4	41
43	Mitochondrial disorders. , 0, , 258-269.		0
44	Blood and cerebrospinal fluid markers in Parkinson's disease: current biomarker findings. Current Biomarker Findings, 0, , 1.	0.4	7